GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Total Payout Yield %

NRXS (Neuraxis) Total Payout Yield % : 0.00 (As of Sep. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Neuraxis's current Total Payout Yield % is 0.00%.


Neuraxis Total Payout Yield % Historical Data

The historical data trend for Neuraxis's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Total Payout Yield % Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Payout Yield %
- - - -27.89

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neuraxis's Total Payout Yield %

For the Biotechnology subindustry, Neuraxis's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Neuraxis's Total Payout Yield % falls into.



Neuraxis Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Neuraxis's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 4.847 + 0) / 17.378763
=-27.89%

Neuraxis's annualized Total Payout Yield % for the quarter that ended in Jun. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 19.0197036
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Neuraxis Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Neuraxis's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042